Erlotinib Prevention of Oral Cancer (EPOC)

Learn more about:
Related Clinical Trial
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma Exfoliated Cytology in Detection of Oral Premalignant and Malignant Lesions The Oral Microbiome in OSCC The Link Between Periodontitis, Smoking and Oral Cancer Research on Optimization and Evaluation of Oral Cancer Screening Methods Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings Topical Aldara (Imiquimod) for Oral Cancer Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions LLL Phototherapy in Oral Lesions Resulting From Anti-neoplastic Treatment Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial Understanding Non-radiotherapy-based Development of Trismus Use of Ultrasound for Measuring Size of Oral Tongue Cancers Green Tea Mouthwash on the Oral Health Status in Oral Cancer Patients Oral Cancer Screening and Education in Hong Kong Evaluating Oral Visual Inspection in the Control of Oral Cancer Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Effects of EMG Visual Feedback for Spinal Accessory Nerve Dysfunction After Neck Dissection: a Randomized Clinical Trial Prevention of Oral DNA Damage by Black Raspberries Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma NBI in Oral Cavity Cancer Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer Physical Activities by Technology Help (PATH) Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients Patient Evaluation for Head and Neck Surgery Branch Studies Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy Prospective Analysis of Robot-Assisted Surgery Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Cigarette Smoking and Oral Microbiota Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. MSOT Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis Least Invasive Nonlinear Light Microscopy Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients Improving Access to Control of Diseases for Women IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Submandibular Gland Preservation in Neck Dissection uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression The Use of Functional Confections in Promoting Oral Health The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis. Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions Wild Type p53 Adenovirus for Oral Premalignancies Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions Trial of IIb Preserving Neck Dissection Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Innovative Approach to Triage Oral Precancer The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Rehabilitation Outcomes in Head and Neck Survivors Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions The Relation of Microtubule-Associated Protein 2 and Cell Migration Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study) Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue Oral Pathology Asynchronous Telementoring Pilot Study Polarized Reflectance Spectroscopy for Oral Lesions A Study of the Effects of PEITC on Oral Cells With Mutant p53 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer – COOLS TRIAL Assessment of Mandibular Bone Invasion With MRI Using SWIFT Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients Epstein-Barr Detection in Oral Cancer Workplace Tobacco Cessation And Oral Cancer Screening Study Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity Personalized Survivor Care Plan for Oral Cancer Patients-Effects on Physical-Psychological Functions and Return-to-Work Dental Hygienists and Dentists as Providers of Oral Mucosa Screening and Brush Biopsies Effects of Mouth-opening Training on the Maximum Interincisal Opening Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy – 3-years Prospective Study Erlotinib Prevention of Oral Cancer (EPOC) Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor. The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer. Validation of DNA Methylation Biomarkers for Oral Cancer Detection Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study Rehabilitation Outcomes of Shoulder Function in Oral Cancer Survivors Cancer Survivors Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions PET/CT and Sentinel Node in Oral Cancer Validation of DNA Methylation Biomarkers for Oral Cancer Detection Web-based Education on Oral Cancer for Primary Care Physicians in Ohio Analysis Of Sensory Recovery Of Donor Size And Quality Life In Oral Cancer Patients Using an APP in Post Oral Cancer Surgery to Affect Patients’ Needs and Quality of Life.

Brief Title

Erlotinib Prevention of Oral Cancer (EPOC)

Official Title

Erlotinib Prevention of Oral Cancer (EPOC)

Brief Summary

      The goal of this clinical research study is to learn if erlotinib hydrochloride (Tarcevaâ
      (OSI-774 ) can prevent cancer in the mouth of people with a high risk of developing cancer in
      the mouth. The safety of this drug will also be studied, as well as the drug's effect on
      different cells in the body.
    

Detailed Description

      Erlotinib hydrochloride is designed to block the activity of an enzyme found on the surface
      of many tumor cells that may control tumor growth and survival. This may keep tumors from
      growing.

      If you are found to be eligible to participate in the study, you will be randomly assigned
      (as in the toss of a coin) to receive either erlotinib hydrochloride or placebo. A placebo is
      a substance that looks like the study drug but has no active ingredients. Neither you nor the
      investigators will know which treatment group you have been assigned to. However, in the
      event of a medical emergency, the study chair can find out which group you are in, if
      necessary. You can be informed which of the groups you were assigned to, after the study has
      ended. There is no certainty that you will have an effect from the treatment, or if you will
      be placed in a group with the active study drug.

      While on study, you will take the study dose (either erlotinib hydrochloride or placebo) by
      mouth, in tablet form, once a day. Tablets should be taken in the morning 1 hour before or 2
      hours after a meal, other medications, vitamins, and iron supplements, with no more than 7
      ounces of water. You should take the study dose around the same time every day. Every attempt
      should be made to keep from vomiting the dose, for at least 30 minutes after taking it. For
      example, if you feel nauseated before or after taking the study dose, anti-nausea medications
      should be used. If you vomit after taking the study dose, the dose can be taken again only if
      the tablet(s) can actually be seen and counted (in other words, they have not dissolved yet).
      You will need to note the time you take each dose of medication throughout the study on a
      calendar that the study nurse will give to you.

      At Months 1, 3, 6, 9, and 12, you will return to clinic. You will have a physical exam
      including measurement of vital signs. You will have a careful examination of the inside of
      your mouth.You will have blood (about 2 teaspoons) drawn for routine tests and to check your
      liver function (about 1-2 teaspoons). At Months 3, 6, and 12, you will have blood (about 2
      teaspoons) drawn for research testing and to measure the level of study drug in the body.

      Your study doctor will ask you about any medications you are taking, how you are feeling
      (symptoms), and your current smoking and alcohol usage.

      The nurse or study coordinator will collect the medication you did not take, as well as your
      completed pill diaries, at every clinic visit. At Months 1, 3, 6, and 9, you will also be
      given new study medication and pill diaries.

      You may also have another small biopsy performed from the inside of your mouth in the area
      where the cells that might become cancerous are located. The biopsy will be performed by your
      doctor and will be sent to a lab for testing. At months 3 and 12, the doctor will also count
      and measure any red or white patches on the inside of your mouth. Biopsies will be taken
      after 3 months of treatment and at the end of 12 months of treatment. The tissue will be
      tested to see if there are any cells that might become cancerous.

      Following the end of treatment, you will return to the clinic every 6 months for 2 years. You
      will have a complete physical exam, including measurement of vital signs. You will have a
      careful examination of the inside of your mouth. You will have blood drawn (about 2
      teaspoons) for routine tests, to check your liver function, and for research testing. Your
      study doctor will ask you about any medications you are taking and how you are feeling
      (symptoms), and your current tobacco and alcohol use.

      In addition, at the final clinic visit, you will also take part in a personal interview.
      During the interview, you will be asked questions regarding socio-demographic information
      (such as age and race), nutrition habits, current and earlier tobacco use, alcohol use
      habits, family history of cancer, use of medications, and how you are feeling. The interview
      will take about 90 minutes to complete. The purpose of the interview is to collect
      information to learn if there is a relationship between certain factors and your risk of
      developing cancer of the mouth. You may be contacted in the future in order to collect more
      information.

      You may be taken off study if you are not able to follow the doctors' instructions, serious
      side effects occur, or the doctor thinks it is in your best interest to leave the study. If
      you are taken off study for any reason, you will be asked to return to the clinic for a final
      clinic visit, preferably within 14 days after leaving the study.

      This is an investigational study. Erlotinib hydrochloride is approved by the FDA for
      treatment of NSCLC. Its use in this study is considered investigational. Approximately 491
      patients will be screened for this study. Up to 120 will be enrolled at MD Anderson.
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Oral Cancer-free Survival in Participants Receiving Erlotinib as Compared With the Control Arm or Placebo Group.


Condition

Oral Cancer

Intervention

Erlotinib

Study Arms / Comparison Groups

 Erlotinib
Description:  Balanced randomization: Erlotinib 150 mg continuous administration for 1 year.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

303

Start Date

November 3, 2006

Completion Date

June 4, 2018

Primary Completion Date

June 4, 2018

Eligibility Criteria

        Inclusion Criteria:

          1. Male or female patients with one of the following: (a) loss of heterozygosity (LOH) at
             3p14 and/or 9p21 in the oral IEN of patients with a history of curatively treated oral
             cancer or (b) LOH at 3p14 and/or 9p21 plus at one other chromosomal region in the IEN
             of patients with no oral cancer history.

          2. Participants must have confirmed diagnosis of oral IEN lesion with LOH. (Note:The
             initial screening biopsy of oral IEN lesion with LOH must be obtained within 12 months
             of study enrollment. If initial diagnostic biopsy for LOH is > 3 months prior to study
             enrollment, investigators may use clinical judgment to order an additional screening
             biopsy to assess histopathological changes).

          3. Age >/= 18 years

          4. ECOG performance status <2

          5. Participants must have normal organ & marrow function as defined below w/in 30 days of
             randomization:CBC w/ differential white cell count-acceptable results must include:WBC
             >3,000ul, hemoglobin>10 g/dl, platelet count > 125,000ul, LFTs-total bilirubin &
             alkaline phosphatase, AST (SGOT) & ALT (SPGT) all w/in <1.5xULN.Note:At the discretion
             of the attending physician,participants w/ Gilbert's disease may still be eligible to
             participate in the event the total bilirubin value is >1.5xULN. Kidney function-serum
             creatinine< 1.5xULN Chemistry-Sodium & potassium all w/in normal institutional limits.

          6. The effects of the study agent on the developing human fetus are unknown.For this
             reason,WOCBP & men must agree to use adequate contraception (hormonal or barrier
             method of birth control;abstinence)prior to study entry& for the duration of active
             treatment.Neg.serum pregnancy test in WOCBP.Childbearing potential will be defined as
             women who have had menses w/in the past 12 mths,who have not had tubal ligation or
             bilateral oophorectomy.Should a woman become pregnant or suspect she is pregnant while
             participating in this study,she should inform her study physician immediately

          7. Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          1. Patients with active cancer or any cancer within the previous two years, excluding
             oral and non-melanoma skin cancer.

          2. Patients with acute intercurrent illness or who have had surgery, radiation therapy,
             or chemotherapy within the preceding 4 weeks unless they have fully recovered.

          3. Patients with a documented history of coagulopathy and/or those taking warfarin or
             warfarin-derivative anticoagulants

          4. Women who are pregnant (confirmed by b-HCG if applicable) or breastfeeding

          5. Any medical or psychological condition or any reason that, according to the
             investigator's judgment, makes the patient unsuitable for participation in the study

          6. Patients who have participated in other experimental therapy studies within 3 months
             of enrollment to this trial

          7. Patients with a history of inflammatory bowel disease

          8. Patients with a documented history of interstitial lung disease
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Vassiliki Papadimitrakopoulou, M.D., , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00402779

Organization ID

2003-0824

Secondary IDs

EPOC

Responsible Party

Sponsor

Study Sponsor

M.D. Anderson Cancer Center

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Vassiliki Papadimitrakopoulou, M.D., Principal Investigator, M.D. Anderson Cancer Center


Verification Date

April 2020